These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29549082)

  • 1. Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015.
    Misra-Hebert AD; Pantalone KM; Ji X; Milinovich A; Dey T; Chagin KM; Bauman JM; Kattan MW; Zimmerman RS
    Diabetes Care; 2018 Jun; 41(6):1164-1171. PubMed ID: 29549082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk prediction for severe hypoglycemia in a type 2 diabetes population with previous non-severe hypoglycemia.
    Misra-Hebert AD; Ji X; Pantalone KM; Hu B; Dey T; Milinovich A; Bauman JM; Zimmerman RS; Kattan MW
    J Diabetes Complications; 2020 Jan; 34(1):107490. PubMed ID: 31757766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Chan SP; Colagiuri S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
    Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
    JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia.
    Thorpe CT; Gellad WF; Good CB; Zhang S; Zhao X; Mor M; Fine MJ
    Diabetes Care; 2015 Apr; 38(4):588-95. PubMed ID: 25592195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability.
    Cheung JTK; Yang A; Wu H; Lau ESH; Lui J; Kong APS; Ma RCW; Luk AOY; Chow E; Chan JCN
    Diabetes Obes Metab; 2024 Aug; 26(8):3339-3351. PubMed ID: 38802991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.
    Moura CS; Rosenberg ZB; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Diabetes Res; 2018; 2018():4817178. PubMed ID: 29713649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis.
    Fu H; Xie W; Curtis B; Schuster D
    Curr Med Res Opin; 2014 Sep; 30(9):1787-93. PubMed ID: 24810150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes.
    Alexopoulos AS; Kahkoska AR; Pate V; Bradley MC; Niznik J; Thorpe C; Stürmer T; Buse J
    JAMA Netw Open; 2021 Nov; 4(11):e2132215. PubMed ID: 34726745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.